This situation highlights the activity profile in cancer cells, where lipogenesis is stimulated and, in turn, there is an increase in the expression of lipogenic enzymes resulting from the oncogenic signaling of the PI3K/Akt and HER2 pathways (Liu 2006) In parallel, the literature reveals the dominant role of the bioenergetic pathway of fatty acid oxidation in prostate cancer and the overexpression of enzymes that participate in this process, such as α-methylacyl-CoA racemase, for branched-chain fatty acid transformation (Wu et al. 2014b; Poulose et al. 2018). The gene discussed is ERBB2; the disease is prostate carcinoma.